Velo3D Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 48% revenue growth year-over-year, driven by defense and aerospace demand and RPS expansion, with gross margin improving to 17.2%. Major defense contracts, a $50M equity raise, and California expansion support guidance for $60–$70M revenue and EBITDA profitability in H2 2026.
Fiscal Year 2025
-
Double-digit revenue growth in 2025 was driven by defense and aerospace demand, with record backlog and a shift toward high-margin RPS. 2026 guidance targets $60–$70 million revenue, gross margins above 30% in H2, and EBITDA positive, supported by strong liquidity and capacity expansion.
-
Revenue grew 65% year-over-year to $13.6M, with backlog rising to $21M and RPS driving recurring revenue. Gross margin improved sequentially, and full-year guidance was reaffirmed, targeting $50–$60M revenue and 30%+ gross margin by Q4.
-
Q2 2025 saw 31% revenue growth, rapid RPS adoption, and major multi-year contracts in space and defense. Gross margin improved, costs declined, and the business model shifted toward recurring, high-margin revenue, with profitability targeted for 2026.
-
The meeting covered director elections, auditor ratification, a reverse stock split, and a governance amendment, all of which were approved by a strong quorum. No questions were raised during the Q&A session. Final voting results will be reported in a Form 8-K.
-
Q1 2025 saw positive gross margin, strong RPS adoption, and improved cost discipline. Revenue was $9.3M, with a growing backlog and major new contracts in defense and aerospace. Guidance for 2025 is reaffirmed, with profitability targeted for 2026.
Fiscal Year 2024
-
Announced a transformative merger and shift to a value-driven model, with Q4 revenue up year-over-year and a strengthened balance sheet. 2025 guidance targets $50–$60 million in revenue and a path to profitability by 2026, leveraging recurring revenue and operational efficiencies.
-
The meeting covered director elections, auditor ratification, a reverse stock split, and share issuance approvals, with all proposals passing. No questions were raised by stockholders, and risks were referenced in SEC filings.